

# Results

## 1<sup>st</sup> Half Year 2011/12

Investor Call  
Mannheim, 29<sup>th</sup> September 2011



Reimund Pohl / Dr. Michael Majerus  
CEO / CFO



© 2011 PHOENIX Pharmahandel GmbH & Co KG

This document has been prepared by PHOENIX Pharmahandel GmbH & Co KG (the “Company” and, together with its subsidiaries and affiliates, “PHOENIX”) solely in connection with the release of the results of the 1<sup>st</sup> half year 2011/12 and is being presented solely for informational purposes. No representation or warranty, express or implied, is or will be made in relation to, and no responsibility is or will be accepted by the Company or any of its respective affiliates, advisors or representatives (together, the “Parties”) as to the accuracy or completeness of the information contained in this document, and nothing in this document shall be deemed to constitute such a representation or warranty. None of the Parties or their respective agents, directors, partners and employees accept any liability whatsoever (in negligence or otherwise) for any loss or damage howsoever arising from any use of this document or its contents or otherwise arising in connection therewith and no reliance should be placed on the information or statements made herein.

This document does not constitute or form part of and should not be construed as a recommendation, offer or invitation for the purchase or subscription of any securities of the Company or any subsidiary, and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.

The information contained in this presentation has not been subject to any independent audit or review. A portion of the information contained in this document, including all market data and trend information, is based on estimates or expectations of the Company, and there can be no assurance that these estimates or expectations are or will prove to be accurate. In addition, past performance of PHOENIX is not indicative of future performance. The future performance of PHOENIX will depend on numerous factors which are subject to uncertainty.

Certain statements contained in this presentation that are not statements of historical fact, including, without limitation, any statements preceded by, followed by or including the words “targets,” “believes,” “expects,” “aims,” “intends,” “may,” “anticipates,” “would,” “could” or similar expressions or the negative thereof, constitute forward-looking statements, notwithstanding that such statements are not specifically identified. In addition, certain statements may be contained in press releases, and in oral and written statements made by or with the approval of the Company that are not statements of historical fact and constitute forward-looking statements. Examples of forward-looking statements include, but are not limited to: (i) statements about future financial and operating results; (ii) statements of strategic objectives, business prospects, future financial condition, budgets, projected levels of production, projected costs and projected levels of revenues and profits of the Company or its management; (iii) statements of future economic performance; and (iv) statements of assumptions underlying such statements.

Forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions which are difficult to predict and outside of the control of the management of the Company. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. You should not place undue reliance on these forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements referenced above. Forward-looking statements speak only as of the date on which such statements are made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement to reflect events or circumstances after the date on which such statement is made, or to reflect the occurrence of unanticipated events.

## Highlights of the 1<sup>st</sup> Half Year 2011/12



Reimund Pohl  
CEO

## Group Financials 1<sup>st</sup> Half Year 2011/12




Dr. Michael Majerus  
CFO


## Questions & Answers

# Facing ongoing market pressure, PHOENIX is able to grow revenue and to increase gross profit

## Revenue



## Gross Profit




- Based on the stable development of business in the first six months of BY 2011/12, PHOENIX group has – with an above-market **revenue** growth – once more confirmed its position as leading pharmaceutical distributor in Europe
- **Gross profit and gross margin** significantly improved as a result of the margin-oriented sales policy, additional higher-margin revenue, and the increasing share of retail business


(mEUR)

# Year-over-year developments of EBITDA and profit before tax confirm the group's solid position

## EBITDA



## Profit before tax



- The increase in **EBITDA** was mainly influenced by the positive development on gross profit level and the decrease in other expenses; the higher cost of personnel and the lower result from participation were over-compensated
- **Profit before tax** is driven by the EBITDA contribution and the improvement in the financial result, mainly due to better-than-planned debt relief and the discontinuation of one-time expenses for the financial restructuring that influenced the previous year

(mEUR)

\* Due to the first-time adoption of IAS 19.93A, PY figures were made comparable

# PHOENIX group grows above market average due to its well-balanced country portfolio



■ PHOENIX wholesale market  
▨ PHOENIX wholesale and retail market

## Well-balanced country portfolio

→ PHOENIX is active in 23 European markets

## Favorable country mix

→ PHOENIX is the undisputed market leader in the fast-growing markets in Northern and Eastern Europe while not being active in the troubled Southern European markets

## Compensation of challenging developments

→ PHOENIX is able to compensate pressure from competitors (e.g. in Germany and France) as well as regulation authorities (e.g. in Germany and UK)

## Growth above market average

→ PHOENIX shows a year-over-year revenue increase of 1.0% for the first half of BY 2011/2012 whereas according to IMS\* the European pharmaceutical markets grew by only 0.2%

The growth strategy is based on a combination of organic growth and careful add-on acquisitions



### Acquisitions to further strengthen the wholesale market position

- Acquisition of a 60% participation in **Farcopa Distribuzione S.r.l.**, a small Italian wholesaler
- Increase of the participation (from 40% to 70%) in **Farmaceutici Signorini S.r.l.**, another regional player in the Italian wholesale market

### Measures to optimize the retail portfolio

- Purposeful **acquisitions and openings of pharmacies** in selected retail markets
- Successful **integration of a pharmacy portfolio in the Netherlands**

### Activities to adjust our participation structure

- Sale of **Imgroma BV**, a marketing and sales company for OTC products in the Netherlands
- In **Poland**, PHOENIX continues to consider **strategic alternatives**; this includes discussions with external investors to find a stronger and more sustainable base for future operations

PHOENIX is well-positioned for the future; this has recently been confirmed by two rating agencies

**STANDARD  
& POOR'S**

**MOODY'S  
INVESTORS SERVICE**

### Standard & Poor's

- On 27 July 2011, the rating agency Standard & Poor's upgraded the **company's rating** from B+ to **BB-** with **continuing positive outlook**
- At the same time, the **bond rating** was improved from B- to **B**

### Moody's

- On 1 August 2011, the rating agency Moody's **upgraded the company's rating** from B1/stable to **B1/positive**



## Group Financials 1<sup>st</sup> Half Year 2011/12



Dr. Michael Majerus  
CFO

# HY P&L reflects the positive profitability development and the ending of restructuring costs



Profit & Loss (in mEUR)	1 <sup>st</sup> HY 2010/11	1 <sup>st</sup> HY 2011/12	Share of revenue	Delta in %
<b>Net turnover</b>	<b>10,769</b>	<b>10,878</b>	<b>100%</b>	<b>1.0%</b>
Cost of goods sold	-9,825	-9,895	-91.0%	0.7%
<b>Gross profit</b>	<b>944</b>	<b>983</b>	<b>9.0%</b>	<b>4.1%</b>
Other income	76	75	0.7%	-0.5%
Personnel expenses	-469	-501	-4.6%	6.9%
Other operative expenses	-282	-274	-2.5%	-2.9%
Result from associates and other invest.	5	2	0.0%	-67.9%
<b>EBITDA</b>	<b>273</b>	<b>284</b>	<b>2.6%</b>	<b>4.0%</b>
Interest from customers	10	12	0.1%	21.8%
Costs of financial restructuring	8	0	0.0%	-100.0%
Factoring fees	3	2	0.0%	-16.2%
<b>Adjusted EBITDA</b>	<b>294</b>	<b>298</b>	<b>2.7%</b>	<b>1.7%</b>
Depreciation	-47	-47	-0.4%	-0.9%
Financial result	-110	-73	-0.7%	-33.6%
<b>PBT</b>	<b>116</b>	<b>164</b>	<b>1.5%</b>	<b>41.5%</b>
Income taxes total	-50	-50	-0.5%	0.0%
<b>Net income</b>	<b>66</b>	<b>115</b>	<b>1.1%</b>	<b>72.6%</b>

## New developments

- **Gross profit** significantly improved as a result of margin-oriented sales policy, additional higher-margin revenue, and the increasing share of retail business
- Improvement allows compensating increased **personnel expenses**, due to first time consolidation of joint venture in the Netherlands, acquisitions in Italy, and normal wage increase
- Other **operative expenses** reduced due to lower level of bad-debt allowances
- As PHOENIX group reduced net debt and is no longer burdened with restructuring costs, **financial result** and in consequence profit before tax are significantly improved
- Improving its effective **tax rate**, PHOENIX is able to maintain tax level despite higher profit before tax

\* Due to the first-time adoption of IAS 19.93A, PY figures were made comparable

# PHOENIX group's optimized financial structure improves the financial result




Financial result (in mEUR)	1 <sup>st</sup> HY 2010/11	1 <sup>st</sup> HY 2011/12	Delta
Interest income	28.1	16.9	-11.2
Interest expenses	-97.3	-87.1	10.2
<b>Interest result</b>	<b>-69.2</b>	<b>-70.2</b>	<b>-1.0</b>
Net exchange effects & change in value of derivatives	-0.7	1.1	1.7
Other financial result	-40.1	-3.8	36.3
<b>Financial result</b>	<b>-109.9</b>	<b>-72.9</b>	<b>37.0</b>

## New developments

- Reduction of interest income due to VEM loan repayment already in BY 2010/2011
- Lower interest expenses are mainly driven by reduced debt
- Other financial result profits from end of restructuring costs

# PHOENIX continues its committed path of strengthening its balance sheet



### New developments of capital structure

- Further deleveraging efforts resulted in reduced financial liabilities
- Equity ratio further improved by profit of the period. Some reducing effects due to continuous recalculation of pension liabilities according to IAS 19.93A, here especially interest effects
- Net Working Capital slightly increased, but on average NWC days still lower than previous year:
  - HY 2011/12: 39.5 days
  - PY 2010/11: 42.1 days
 Inventories grow due to seasonal fluctuations. Receivables and payables increased mainly due to second Italian acquisition


- Financial Liabilities
- Cash & Equivalents
- Equity
- Net Working Capital
- Other

(mEUR)


\* Due to the first-time adoption of IAS 19.93A, PY figures were made comparable.

# Net Debt is significantly improved compared to previous years

07/31/2011



07/31/2010\*



(mEUR)

## Y-o-Y developments

- Net Debt reduction of 1.6 bnEUR compared to 1<sup>st</sup> HY 2010/11:
  - 506 mEUR equity increase
  - 459 mEUR VEM loan repayment
  - 650 mEUR cash flow contribution
- Significant optimization of debt structure
- Reduced cash position


## 1<sup>st</sup> HY developments

- After slight Net Debt increase in Q1 by 0.2 bnEUR, Net Debt is almost back on low level of last year end of 2,177 mEUR

# Solid financial structure after refinancing provides meaningful financial flexibility


## Headroom financial facilities

07/31/2011



- Diversified financing structure
- Strong cash generation allowed reducing SFA term loan by (-100 mEUR) in Q2 2011/12
- Optimization by reallocating of 200 mEUR from SFA term loan into SFA revolver


## Debt maturity profile



- Since end of last financial year PHOENIX extended maturities for 0.6 bnEUR until end of 2015
- With the extension of maturities beyond the maturity of the high yield bond banks signal their confidence in PHOENIX's credit worthiness

(mEUR)

# The cumulative cash flow for the 1<sup>st</sup> half year shows a positive free cash flow



## Cash flow development

- Improved profit of the period and reduced changes in working capital lead to a positive free cash flow
- Some negative effects from 'Other non-cash expenses/income, interests, taxes, and dividends'
- Cash flow from investing activities on comparable level
- As expected, the second quarter compensates the negative swing of working capital from the 1<sup>st</sup> quarter

(mEUR)

\* Due to the first-time adoption of IAS 19.93A, PY figures were made comparable

# Summary: Development of key credit indicators

	01/31/2011	07/31/2011	Delta in %
Equity (in mEUR)	1,761.1 *	1,814.4	3.0%
Equity Ratio	23.2%	24.1%	3.9%
Net Debt (in mEUR)	2,176.6	2,183.9	0.3%
Gearing (Net debt/Equity)	1.24	1.20	-2.6%




	1 <sup>st</sup> HY 2010/11	1 <sup>st</sup> HY 2011/12	Delta in %
EBITDA (in mEUR)	273.4 *	284.3	4.0%
EBITDA-Margin	2.54%	2.61%	2.9%
Adjusted EBITDA (in mEUR)	293.6 *	298.4	1.7%
Adj.-EBITDA-Margin	2.73%	2.74%	0.6%
Interest Coverage Ratio (EBIT / Interest Expenses)	2.32	2.73	17.4%



\* Due to the first-time adoption of IAS 19.93A, PY figures were made comparable



# The price development of the PHOENIX bond reflects the increased market margins



Despite the market and regulatory pressure in some countries and struggling competitors, **PHOENIX group maintains its outlook for 2011/12**

- Revenue growth to slightly outpace the market in 2011/12
- Adjusted EBITDA 2011/12 to exceed 2010/11 level
- Selective investments in property, plant and equipment
- Reduction of net financial liabilities compared to end of 2010/11

# PHOENIX group with unchanged stringent financial policy

## Deleveraging strategy

- Further deleveraging is integral part of PHOENIX's financial policy and is backed by its main shareholders
- Net Debt/EBITDA target of around 3.0x
- PHOENIX is confident to reach its leverage target in the next two years

## No regular dividend payments

- In line with PHOENIX's deleveraging strategy, no regular dividend payments are planned for the next three years
- Loan and bond documentation also include dividend restrictions

## Carefully managed acquisition activity

- PHOENIX's growth strategy is focused on above market organic growth
- Profitable and financially sound add-on acquisitions (mainly pharmacies) may also be pursued, but only within a predefined acquisition budget

**PHOENIX** group